Skip to main content

Table 1 Mean percent blood glucose reduction in normal rats (N = 6)

From: Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models

Time

(h)

Gliclazide

Efavirenz

Efavirenz + Gliclazide (Single dose treatment)

Efavirenz + Gliclazide (Multiple dose treatment)

1

31.46 ± 1.39

-06.66 ± 2.95

24.40 ± 1.20***

26.57 ± 1.09*

2

41.64 ± 0.80

-04.44 ± 1.44

33.77 ± 0.87**

36.26 ± 1.53*

3

28.21 ± 0.95

-02.94 ± 0.96

21.19 ± 1.15***

22.26 ± 0.99**

4

24.21 ± 1.13

-00.06 ± 1.80

16.16 ± 0.79***

18.68 ± 0.96***

6

31.47 ± 1.46

02.14 ± 1.49

23.34 ± 1.09***

28.71 ± 1.85

8

38.70 ± 1.43

04.29 ± 1.09

28.36 ± 1.70***

31.21 ± 2.03**

10

26.08 ± 1.02

06.86 ± 1.78

19.00 ± 1.44***

20.45 ± 1.11**

12

12.27 ± 1.55

06.13 ± 1.59

08.27 ± 0.64

08.98 ± 1.02

  1. ***Significant at P < 0.001 compared to gliclazide control
  2. **Significant at P < 0.01 compared to gliclazide control
  3. *Significant at P < 0.05 compared to gliclazide control